Viewpoint Molecular Targeting, a radiopharmaceutical company based in Coralville, last week announced the successful completion of a merger with medical technology company Isoray.
Coralville, Iowa-based Viewpoint and Richland, Washington-based Isoray announced their intent to merge back in September. Having completed the merger, the combined company now has access to Isoray's radioactive isotope, cesium-131, which is…
Viewpoint Molecular Targeting, a radiopharmaceutical company based in Coralville, announced last week plans to merge with medtech company Isoray.
Under the terms of the agreement, a newly formed wholly-owned subsidiary of Isoray will merge with and into Viewpoint, with Viewpoint continuing as the surviving corporation and a subsidiary of Isoray.
“I believe the combination of…
Viewpoint Molecular Targeting, a radiopharmaceutical company based in Coralville, has been awarded a total of $5 million in Phase II grants from the National Cancer Institute under the SBIR program and National Institutes of Health (NIH).
The grants will be used to advance the company’s proprietary image-guided radiotherapies in development to optimize treatment that…
Viewpoint Molecular Targeting, a radiopharmaceutical company based in Coralville, announced last week that it has closed its third and final tranche of Series A financing, bring the round to a total of approximately $13 million.
Proceeds from the financing will be used to advance the Company’s two lead programs, VMT01 and VMT- 𝛼-NET, into Phase…
Viewpoint Molecular Targeting, a pharmaceutical startup based in Coralville, has raised $8 million in Series A financing.
Viewpoint is a University of Iowa startup pharmaceutical company that has developed novel therapy and companion diagnostics for cancer. The company says it expects to complete one or more additional tranches of this financing on the same terms over the next…
